Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Alumis Inc.

ALMS Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025

Last close · Oct 23, 2026

$6.78

0.6%
Compare
Revenue Total sales reported in the income statement.
$24.1M
vs prior year
Operating margin Operating income as a share of revenue.
−1,886.9%
Net income Profit after all expenses, interest and tax.
−$243M
Free cash flow Cash from operations minus capital spending.
−$370M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
$866M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$3.66 EPS (TTM)

What Alumis Inc. does

No business description yet.

Legal name
ALUMIS INC.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Mar 19, 2026
Accession · CIK
0001847367-26-000006
0001847367

Revenue and margins

Alumis Inc. had $24.1M of revenue in fiscal 2025.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$370M in fiscal 2025, −1,539.2% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Alumis Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 200.0%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Alumis Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY23FY24FY25
Cash and short-term investments $49.0M$288M$309M
Current ratio 2.6x6.0x4.3x
Quick ratio 2.6x6.0x4.3x
Total assets $89.6M$341M$412M
Total liabilities $53.5M$80.9M$111M
Shareholders' equity −$339M$260M$301M
Net debt (− = net cash) ———

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✕ ✕ ✕
Cash from operations is positive ✕ ✕ ✕
Return on assets rose — ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✕
Debt fell relative to assets — — —
Current ratio rose — ✓ ✕
Share count didn't rise — ✕ ✕
Gross margin rose — — —
Revenue rose relative to assets — — —
F-score — / 3— / 6— / 6
Accruals ratio −27.9%−18.2%33.5%
Altman Z'' −29.40−3.94−7.78

3 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY23FY24FY25
Income statement
Revenue — — $24.1M
Research and development $138M $266M $386M
Operating income −$158M −$301M −$454M
Pretax income — −$294M −$252M
Income tax $0.0M $0.0M −$8.6M
Net income −$155M −$294M −$243M
Diluted EPS −$72.08 −$10.38 −$2.86
Diluted shares 0.00B 0.03B 0.09B
Cash flow
Cash from operations −$130M −$255M −$370M
Capital expenditure $4.5M $1.7M $0.7M
Free cash flow −$134M −$257M −$370M
Depreciation and amortization $1.3M $3.2M $3.5M
Stock-based compensation $8.6M $19.5M $43.5M
Share buybacks $0.1M $0.0M $0.0M
Dividends and buybacks $0.1M $0.0M $0.0M
Balance sheet
Cash and short-term investments $49.0M $288M $309M
Finance lease liabilities $0.0M $0.0M $0.0M
Current assets $53.4M $306M $318M
Current liabilities $20.9M $50.9M $73.3M
Property and equipment, net $22.4M $21.0M $18.2M
Total assets $89.6M $341M $412M
Total liabilities $53.5M $80.9M $111M
Shareholders' equity −$339M $260M $301M
Margins
Operating margin — — −1,886.9%
EBITDA margin — — −1,872.4%
Net margin — — −1,011.7%
FCF margin — — −1,539.2%
Returns
Return on capital employed −230.1% −103.7% −134.0%
Return on equity — — −86.7%
Return on assets −173.0% −136.7% −64.6%
Return on tangible equity — −113.1% −80.8%
Growth
Share count change — 1,218.1% 200.0%
Financial health
Current ratio 2.6x 6.0x 4.3x
Quick ratio 2.6x 6.0x 4.3x
Capital allocation
Capex / revenue — — 2.7%
Stock comp / revenue — — 181.0%
Quality scores
Altman Z'' −29.4 −3.9 −7.8
Accruals ratio −27.9% −18.2% 33.5%

Source: SEC EDGAR XBRL filings (CIK 0001847367). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open